Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Lymphocytes, Tumor-Infiltrating
  • Triple Negative Breast Neoplasms

abstract

  • In two national randomized clinical trials using contemporary adjuvant chemotherapy, we confirm that stromal lymphocytic infiltration constitutes a robust prognostic factor in TNBCs. Studies assessing outcomes and therapeutic efficacies should consider stratification for this parameter.

publication date

  • September 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4162494

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.55.0491

PubMed ID

  • 25071121

Additional Document Info

start page

  • 2959

end page

  • 66

volume

  • 32

number

  • 27